XBIT
Neutral signalScored 2026-10-28 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
XBiotech Inc.
- Nom
- XBiotech Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $58.8M
- Employés
- 87
- PDG
- Sushma Shivaswamy
- Site web
- https://www.xbiotech.com
- Marché
- ACETACRVADAGCRVOFBIOGANX
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 368 524 titres (~711 251,32 $ US)
- Insiders
- SIMARD JOHN
- Total bought
-
$711,251
Avg buy (VWAP, 90d window) $1.93 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-10-26
- Last synced
-
2026-10-29 10:33:26
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-26 | SIMARD JOHN | Buy · P P · 10b5-1: not stated | 368,524 | $1.93 | ≈ $711,251 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-28 Drivers: fundamentals. Moteurs : fondamentaux.
XBIT presents a compelling event-driven signal — a large insider cluster buy following positive Phase II TASKIN trial results and a new Co-CEO appointment — suggesting strong insider conviction in the clinical pipeline.
The first sentence of the analysis written for XBIT on 2026-10-28 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 16.01 · operating margin 0.0%
Recent news
- 2026-10-23 XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers AUSTIN, Texas, Oct. 23, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside CEO Dr. Sushma Shivaswamy, effective Oct. 23, 2026.
- 2026-10-19 XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer Investigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy success criterion with 61.3% 12-month overall survival.
- 2026-09-15 XBiotech (NASDAQ:XBIT) Stock Price Crosses Below 50-Day Moving Average – What’s Next? XBiotech Inc. (NASDAQ: XBIT - Get Free Report)''s stock price passed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $2.27 and traded as low as $2.17. XBiotech shares last traded at $2.17, with a volume of 21,881 shares trading hands. Analyst Ratings Changes Separately,
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 83.8% | 68.4% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | -837.6% | -138.4% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | -772.4% | -124.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | -860.1% | -136.4% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | -837.6% | -138.4% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | -820.4% | -94.7% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | -820.4% | -94.7% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | -820.4% | -94.7% | |
| Current Ratio | 16.011 | 11.557 | 33.069 | 54.069 | 71.494 | |
| Quick Ratio | 16.011 | 11.557 | 33.069 | 54.069 | 71.494 | |
| Solvency Ratio | -4.506 | -2.186 | -2.936 | -5.312 | -2.549 | |
| Cash Ratio | 15.834 | 11.432 | 32.791 | 38.688 | 68.631 | |
| Price To Earnings Ratio | -1.604 | -3.135 | -4.938 | -3.250 | -19.190 | |
| Price To Earnings Growth Ratio | -0.088 | -0.056 | 0.198 | -0.038 | -0.314 | |
| Forward Price To Earnings Growth Ratio | -0.088 | -0.056 | 0.198 | -0.038 | -0.314 | |
| Price To Earnings Diluted Ratio | -1.604 | -3.135 | -4.938 | -3.250 | -19.190 | |
| Price To Earnings Diluted Growth Ratio | -0.088 | -0.056 | 0.198 | -0.038 | -0.314 | |
| Price To Book Ratio | 0.519 | 0.660 | 0.554 | 0.444 | 1.241 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 26.644 | 18.179 | |
| Price To Free Cash Flow Ratio | -1.812 | -3.729 | -6.353 | -6.934 | 5.073 | |
| Price To Operating Cash Flow Ratio | -1.825 | -3.886 | -6.476 | -7.207 | 4.815 | |
| Debt To Assets Ratio | 0.000 | 0.051 | 0.000 | 0.000 | 0.000 | |
| Debt To Equity Ratio | 0.000 | 0.056 | 0.000 | 0.000 | 0.000 | |
| Debt To Capital Ratio | 0.000 | 0.053 | 0.000 | 0.000 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.069 | 1.092 | 1.035 | 1.024 | 1.022 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.017 | 0.065 | |
| Operating Cash Flow Ratio | -5.035 | -2.050 | -3.070 | -3.646 | 20.111 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | -3.697 | 3.775 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.007 | 1.042 | 1.019 | 1.039 | 0.949 | |
| Debt Service Coverage Ratio | -497.341 | -3.254 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | -632.784 | -52.628 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | -3.021 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.000 | -3.021 | 0.000 | 0.000 | 0.000 | |
| Capital Expenditure Coverage Ratio | -138.131 | -23.745 | -51.727 | -25.340 | 19.701 | |
| Dividend Paid And Capex Coverage Ratio | -138.131 | -23.745 | -51.727 | -25.340 | 0.884 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -4.307 | |
| Enterprise Value Multiple | 1.210 | 1.169 | 3.490 | 1.629 | -4.270 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | ▼-30.4% |
| Ebit Margin | 0.0% | 0.0% | ▲195.2% |
| Ebitda Margin | 0.0% | 0.0% | ▲179.3% |
| Operating Profit Margin | 0.0% | 0.0% | ▲199.3% |
| Pretax Profit Margin | 0.0% | 0.0% | ▲195.2% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | ▲183.0% |
| Net Profit Margin | 0.0% | 0.0% | ▲183.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | ▲183.0% |
| Current Ratio | 16.011 | ▲4.454 | ▼-21.229 |
| Quick Ratio | 16.011 | ▲4.454 | ▼-21.229 |
| Solvency Ratio | -4.506 | ▼-2.320 | ▼-1.008 |
| Cash Ratio | 15.834 | ▲4.403 | ▼-17.641 |
| Price To Earnings Ratio | -1.604 | ▲1.531 | ▲4.819 |
| Price To Earnings Growth Ratio | -0.088 | ▼-0.031 | ▼-0.028 |
| Forward Price To Earnings Growth Ratio | -0.088 | ▼-0.031 | ▼-0.028 |
| Price To Earnings Diluted Ratio | -1.604 | ▲1.531 | ▲4.819 |
| Price To Earnings Diluted Growth Ratio | -0.088 | ▼-0.031 | ▼-0.028 |
| Price To Book Ratio | 0.519 | ▼-0.141 | ▼-0.165 |
| Price To Sales Ratio | 0.000 | 0.000 | ▼-8.965 |
| Price To Free Cash Flow Ratio | -1.812 | ▲1.917 | ▲0.939 |
| Price To Operating Cash Flow Ratio | -1.825 | ▲2.061 | ▲1.091 |
| Debt To Assets Ratio | 0.000 | ▼-0.051 | ▼-0.010 |
| Debt To Equity Ratio | 0.000 | ▼-0.056 | ▼-0.011 |
| Debt To Capital Ratio | 0.000 | ▼-0.053 | ▼-0.011 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.069 | ▼-0.023 | ▲0.021 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | ▼-0.017 |
| Operating Cash Flow Ratio | -5.035 | ▼-2.985 | ▼-6.297 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | ▼-0.016 |
| Free Cash Flow Operating Cash Flow Ratio | 1.007 | ▼-0.035 | ▼-0.004 |
| Debt Service Coverage Ratio | -497.341 | ▼-494.087 | ▼-397.222 |
| Interest Coverage Ratio | -632.784 | ▼-580.156 | ▼-495.702 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▲3.021 | ▲0.604 |
| Operating Cash Flow Coverage Ratio | 0.000 | ▲3.021 | ▲0.604 |
| Capital Expenditure Coverage Ratio | -138.131 | ▼-114.387 | ▼-94.283 |
| Dividend Paid And Capex Coverage Ratio | -138.131 | ▼-114.387 | ▼-90.520 |
| Dividend Payout Ratio | 0.000 | 0.000 | ▲0.861 |
| Enterprise Value Multiple | 1.210 | ▲0.041 | ▲0.565 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $72.9M | $120.3M | $121.3M | $106.8M | $334.4M | |
| Enterprise value | -$52.7M | -$42.1M | -$78.8M | -$50.5M | $97.4M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | -12.59x | 5.29x | |
| EV / Op. cash flow | 1.32x | 1.36x | 4.21x | 3.40x | 1.40x | |
| EV / Free cash flow | 1.31x | 1.30x | 4.13x | 3.27x | 1.48x | |
| EV / EBITDA | 1.21x | 1.17x | 3.49x | 1.63x | -4.27x | |
| Net debt / EBITDA | 2.88x | 4.51x | 8.86x | 5.08x | 10.39x | |
| Current ratio | 16.01x | 11.56x | 33.07x | 54.07x | 71.49x | |
| Income quality | 0.88x | 0.80x | 0.76x | 0.45x | -3.99x | |
| Graham net-net | $4 | $5 | $6 | $7 | $8 | |
| Tax burden | 100.5% | 99.9% | 101.0% | 98.0% | 68.4% | |
| Interest burden | 100.2% | 102.1% | 100.0% | 100.0% | 100.0% | |
| Working capital | $119.0M | $159.5M | $195.6M | $215.8M | $243.4M | |
| Invested capital | $142.2M | $184.0M | $220.5M | $242.0M | $271.7M | |
| Return on assets | -30.3% | -19.4% | -10.8% | -13.4% | -6.3% | |
| Operating ROA | -31.9% | -20.0% | -15.9% | -13.2% | -8.0% | |
| Return on tangible assets | -30.3% | -19.4% | -10.8% | -13.4% | -6.3% | |
| Return on equity | -32.4% | -21.1% | -11.2% | -13.7% | -6.5% | |
| Return on invested capital | -39.2% | -21.8% | -17.0% | -14.0% | -6.3% | |
| Return on capital employed | -39.2% | -23.1% | -17.0% | -14.2% | -9.2% | |
| Earnings yield | -62.5% | -32.0% | -20.3% | -30.8% | -5.2% | |
| Free cash flow yield | -55.2% | -26.8% | -15.7% | -14.4% | 19.7% | |
| Capex / Op. cash flow | -0.7% | -4.2% | -1.9% | -3.9% | 5.1% | |
| Capex / Depreciation | 17.1% | 74.7% | 20.8% | 22.4% | 133.1% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 14.6% | 19.2% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 157.2% | 51.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 786.6% | 153.7% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 126.2% | 24.3% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 161d | 178d | |
| Days payables outstanding | 332d | 0d | 0d | 1350d | 130d | |
| Operating cycle | 0d | 0d | 0d | 161d | 178d | |
| Cash conversion cycle | -332d | 0d | 0d | -1190d | 48d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years